{"id":470591,"date":"2021-04-05T07:03:34","date_gmt":"2021-04-05T11:03:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470591"},"modified":"2021-04-05T07:03:34","modified_gmt":"2021-04-05T11:03:34","slug":"oncolytics-biotech-to-host-key-opinion-leader-webinar-to-discuss-aware-1-data-the-immunotherapeutic-effects-of-pelareorep-in-breast-cancer-and-its-synergistic-activity-with-car-t-cells-in-soli","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-key-opinion-leader-webinar-to-discuss-aware-1-data-the-immunotherapeutic-effects-of-pelareorep-in-breast-cancer-and-its-synergistic-activity-with-car-t-cells-in-soli\/","title":{"rendered":"Oncolytics Biotech\u00ae to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors"},"content":{"rendered":"
\n

Webinar will take place Monday April 12, 2021 at 2:00 pm ET<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span> and CALGARY, AB<\/span>, April 5, 2021<\/span> \/PRNewswire\/ — Oncolytics Biotech\u00ae<\/sup>\u00a0Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors. The webinar will take place on Monday, April 12, 2021<\/span> at 2:00 pm ET<\/span>.<\/p>\n

The webinar will feature presentations by Key Opinion Leaders Aleix Prat<\/span>, M.D., Ph.D. (Cl\u00ednic Barcelona<\/span>) and Richard Vile<\/span>, Ph.D., (Mayo Clinic). Dr. Prat’s portion of the presentation will focus on data from the AWARE-1 window-of-opportunity clinical trial evaluating pelareorep with and without atezolizumab (Tecentriq\u00ae<\/sup>) in early-stage breast cancer, which will be presented at this year’s American Association for Cancer Research (AACR) Annual Meeting. Dr. Vile will then discuss the results of a preclinical study evaluating pelareorep and chimeric antigen receptor (CAR) T cell combination therapy in solid tumors (link<\/a>\u00a0to PR, link<\/a>\u00a0to poster).<\/p>\n

During the event, Oncolytics’ management team will also give a corporate update and discuss the company’s upcoming milestones. Dr. Prat, Dr. Vile, and company management will be available to answer questions following the formal presentations.<\/p>\n

To register for the event, please click here<\/a>.<\/p>\n

\n About the KOLs<\/b>\n <\/p>\n

\n
\n
\n Aleix Prat<\/span>, M.D., Ph.D.<\/i>
\n <\/b>
\n \u00a0<\/i>is the Head of the Medical Oncology Department of the Hospital Cl\u00ednic Barcelona<\/span> (Spain<\/span>), Associate Professor at the University of Barcelona<\/span>, Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Lab at IDIBAPS, and President of the governing board of the Spanish Breast Cancer Cooperative Research Group (SOLTI), which performs clinical trials of excellence in oncology. He was also named a member of the Executive Board of The Breast International Group (BIG) in 2018. BIG is an international non-profit organization that is linked to more than 3,000 hospitals and includes more than 10,000 experts and more than 56 cooperative groups from around the world.<\/p>\n

Over his career, Dr. Prat obtained worldwide prestige as a research scientist in the field of breast cancer genomics and biomarker development. In 2008, he became a postdoctoral research associate (2008-2012) at the Lineberger Comprehensive Cancer Center (University of North Carolina at Chapel Hill<\/span>, USA<\/span>) in the Laboratory of Prof. Charles M. Perou<\/span>, a world-renowned translational researcher in breast cancer. During this postdoctoral experience, he discovered and characterized a new molecular subtype of breast cancer, known as a Claudin-low (Prat et al. Breast Cancer Research 2010; Citations: 1,518). In addition, he contributed to the breast cancer portion of The Cancer Genome Atlas (Nature 2012; Citations: 4,661), which was a landmark molecular characterization study in the field of cancer research.<\/p>\n

\n
\n
\n Richard Vile<\/span>, Ph.D.<\/i>
\n <\/b>\u00a0is a world-renowned scientist and member of the Oncolytics Scientific Advisory Board with extensive experience studying pelareorep. As a recognized KOL, his research focuses on several areas of immuno-oncology, including oncolytic viruses, adoptive cell therapies (ACTs) such as chimeric antigen receptor (CAR) T cells, and potential synergistic interactions between oncolytic viruses and ACTs. In addition to his role as a professor at the Mayo Clinic (“Mayo”), Dr. Vile is the Director of Mayo’s Immuno-oncology and Gene and Virus Therapy programs and Co-Director of the Cancer Immunology and Immunotherapy program. He also serves on the editorial board of several prestigious scientific journals, including Molecular Therapy, Gene Therapy, The Journal of Gene Medicine<\/span>, and OncoImmunology. Dr. Vile received his B.A. in Biochemistry from the University of Oxford<\/span> and his Ph.D. in Viral Vectors from the University of London.\u00a0<\/p>\n

\n About AWARE-1
<\/b>AWARE-1 is an open label window-of-opportunity study in early-stage breast cancer enrolling 38 patients into five cohorts:<\/p>\n